Overview
Dr. Brown is an expert in liver diseases, including alcohol-related liver disease, which affects up to 20 percent of the population, chronic hepatitis C infection, which affects an estimated 2.4 million Americans and cirrhosis, a scarring of the liver that is the third most common disease-related cause of death in the United States. Dr. Brown has co-authored over 200 peer-reviewed articles published in leading, peer-reviewed journals, including the New England Journal of Medicine, Nature, Gastroenterology, Hepatology, the American Journal of Transplantation, Clinical Infectious Diseases, and JAMA Surgery. He has also held editorial and editorial board roles for several premier journals in the hepatology field, including his current position as Editor-In-Chief of Liver Transplantation since February 2020.
Highlights
- 1Hepatology (Baltimore, Md.) · 2021
- 2Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
- 3Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2023
Publications
Funding
Active
3 grants- KPT32DK116970-06A1Multidisciplinary Research Training in Gastroenterology and HepatologyNational Institute of Diabetes and Digestive and Kidney Diseases · 2025–2030Training
- PIR34AA033514-01Implementation and Pilot of the LIFT Model for Post-Transplant Alcohol Use Disorder CareNIAAA · 2026–2029 · via NIH RePORTER
- PIU01DK130221-06Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis NetworkNational Institute of Diabetes and Digestive and Kidney Diseases · 2021–2027· 3 renewals
Completed grants (3)
- Sub-PIU01AA021908-05Molecular Subtypes for Targeted Therapies in Alcoholic HepatitisNational Institute on Alcohol Abuse and Alcoholism · 2016–2018 · via University of Pittsburgh· 2 renewals
- PIU01DK060324-05Race & Viral Resistance in Chronic Hepatitis C (VIRAHEP*NIDDK · 2001–2006 · via NIH RePORTER
- MPIM01RR000645-32ADEFOVIR DIPIVOXIL FOR PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTIONNCRR · 2000–2002 · via NIH RePORTERNo publications yet
Clinical research
Active
2 studies- PINCT05832229Liver Cirrhosis Network (LCN) Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 StudyPHASE2 · National Institute of Diabetes & Digestive & Kidney Diseases · OPEN TO ACCRUAL (as of 2023)Cirrhosis; Cirrhosis, Liver; Cirrhosis Early; Cirrhosis Due to Hepatitis B; Cirrhosis Advanced; Cirrhosis Infectious; Cirrhosis Alcoholic; Cirrhosis Due to Hepatitis C
- PINCT05740358Liver Cirrhosis Network Cohort StudyNational Institutes of Health · OPEN TO ACCRUAL (as of 2022)Cirrhosis; Cirrhosis, Liver; Cirrhosis Early; Cirrhosis Due to Hepatitis B; Cirrhosis Advanced; Cirrhosis Infectious; Cirrhosis Alcoholic; Cirrhosis, Biliary; Cirrhosis Cryptogenic; Cirrhosis Due to Hepatitis C; Cirrhosis Due to Primary Sclerosing Cholangitis; Autoimmune Hepatitis
Completed & closed trials (9)
- PINCT05582681HCV Test and Treat Utilizing Simplified HCV Patient EducationPHASE4 · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)Hepatitis C
- PINCT03692897An Observational Study of Patients With Chronic Hepatitis B (CHB) InfectionTARGET PharmaSolutions, Inc. · IRB STUDY CLOSURE (as of 2025)Hepatitis B; Hepatitis; Liver Diseases
- PINCT04903626A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents With Acute Hepatitis C Virus (HCV) InfectionPHASE3 · AbbVie Inc. · IRB STUDY CLOSURE (as of 2024)Hepatitis C Virus (HCV)
- PIWearAble Technology to evaluate impact of Covert Hepatic Encephalopathy on Sleep (WATCHES) StudyWeill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
- PINCT04563026A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Alcoholic HepatitisPHASE2 · DURECT Corporation · IRB STUDY CLOSURE (as of 2023)Alcoholic Hepatitis
- PINCT05309200A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Adaptive Dose-Ranging Study to Assess Safety and Efficacy of Intravenous OCE-205 in Adults Diagnosed With Cirrhosis With Ascites Who Have Developed Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)PHASE2 · Ocelot Bio, Inc. · IRB STUDY CLOSURE (as of 2023)Cirrhosis; Ascites; Hepatorenal Syndrome; Acute Kidney Injury
- PIPatient and Caregiver Reported Outcomes in Adult Liver Transplant RecipientsThe General Hospital Corporation (dba Massachusetts General Hospital) · IRB STUDY CLOSURE (as of 2023)
- PINCT04378010A Phase 2b Randomized, Double-Blind, Placebo-controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-alcoholic Steatohepatitis (NASH) (ARGON-2)PHASE2 · Enanta Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2022)Non-Alcoholic Steatohepatitis
- PINCT03781726A Multi-Center, Open-Label Study of Glecaprevir/Pibrentasvir to Treat Recipients of Transplanted Kidneys From Deceased Donors With Hepatitis C VirusPHASE4 · The General Hospital Corporation (dba Massachusetts General Hospital) · IRB STUDY CLOSURE (as of 2021)Renal Failure Chronic; Hepatitis C
News mentions
- NIH Grant Funds Clinical Research on CirrhosisOctober 15, 2021
Weill Cornell Medicine has received a $2 million grant from the National Institutes of Health (NIH) to participate in a multicenter clinical initiative focused on understanding and treating cirrhosis, scarring of the liver that leads to the organ’s failure and increases the risk of liver cancer.
- Dr. Robert S. Brown Named Chief of Division of Gastroenterology and Hepatology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical CenterSeptember 10, 2021
Dr. Robert S. Brown, an outstanding physician-scientist who combines clinical care with research focused on improving outcomes for patients with liver diseases, has been named chief of the Division of Gastroenterology and Hepatology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective Aug. 1.
- Black Patients with Liver Disease May Face Obstacles to Placement on the Liver Transplant WaitlistJuly 2, 2021
Black patients who have chronic liver failure, also known as end stage liver disease (ESLD), are less likely to be placed on a waiting list for a life-saving liver transplant than other racial and ethnic groups, according to a study of national databases by investigators at Weill Cornell Medicine, NewYork-Presbyterian and Columbia University Vagelos College of Physicians and Surgeons.
- Eight-Week Oral Drug Treatment Cures Hepatitis C Infection in 98% of Patients with Compensated CirrhosisJanuary 10, 2020
An eight-week course of treatment with the daily oral drug glecaprevir/pibrentasvir cured chronic hepatitis C virus (HCV) infection in 98% of previously untreated patients with an asymptomatic form of cirrhosis or liver scarring known as compensated cirrhosis.
Media highlights
- Here’s Exactly What Happens To Your Liver When You Eat EggsParade Magazine · August 17, 2026
Mentoring
- MAMark Alexander GrossmanPostdoc mentee · 2020–2026
- MJMyeong Joon KimPostdoc mentee · 2024–2026
- AJAnn JosephPostdoc mentee · 2021–2023
External relationships
Other
AbbVie Inc. · Bausch Health · Genentech, Inc. · Gilead Sciences, Inc. · GSK Research & Development Limited · Intercept Pharmaceuticals, INC · Ipsen Pharma S.A.S. · Madrigal Pharmaceuticals, Inc. · Mallinckrodt, Inc. · Mirum Pharmaceuticals, Inc. · Salix Pharamaceuticals, Inc.